pioglitazone has been researched along with Dunnigan Syndrome in 9 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pioglitazone was added to her treatment, and follow-up showed improvement of metabolic control 7 months after introducing pioglitazone, and improvement of insulin sensitivity 2 years later." | 7.75 | Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report. ( Beressi, JP; Billon-Bancel, A; Collet-Gaudillat, C, 2009) |
| " Pioglitazone was added to her treatment, and follow-up showed improvement of metabolic control 7 months after introducing pioglitazone, and improvement of insulin sensitivity 2 years later." | 3.75 | Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report. ( Beressi, JP; Billon-Bancel, A; Collet-Gaudillat, C, 2009) |
| "The laminopathy variant familial partial lipodystrophy type 2 or Dunnigan syndrome (FPLD2) is the most common cause of partial LD." | 1.42 | [Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia]. ( Kalashnikova, MF; Melnichenko, GA; Sorkina, EL; Tyulpakov, AN, 2015) |
| "Pioglitazone was markedly effective in glycemic control in this case." | 1.35 | Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy. ( Chen, W; Ebihara, K; Hosoda, K; Ito, J; Iwanishi, M; Kusakabe, T; Masuzaki, H; Nakao, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Iizaka, T | 1 |
| Kodama, E | 1 |
| Mikura, K | 1 |
| Iida, T | 1 |
| Imai, H | 1 |
| Hashizume, M | 1 |
| Kigawa, Y | 1 |
| Sugisawa, C | 1 |
| Tadokoro, R | 1 |
| Endo, K | 1 |
| Otsuka, F | 1 |
| Isoda, M | 1 |
| Ebihara, K | 2 |
| Ishibashi, S | 1 |
| Nagasaka, S | 1 |
| Agostini, M | 1 |
| Schoenmakers, E | 1 |
| Beig, J | 1 |
| Fairall, L | 1 |
| Szatmari, I | 1 |
| Rajanayagam, O | 1 |
| Muskett, FW | 1 |
| Adams, C | 1 |
| Marais, AD | 1 |
| O'Rahilly, S | 2 |
| Semple, RK | 1 |
| Nagy, L | 1 |
| Majithia, AR | 1 |
| Schwabe, JWR | 1 |
| Blom, DJ | 1 |
| Murphy, R | 1 |
| Chatterjee, K | 2 |
| Savage, DB | 2 |
| Sorkina, EL | 1 |
| Kalashnikova, MF | 1 |
| Melnichenko, GA | 1 |
| Tyulpakov, AN | 1 |
| Tan, GD | 1 |
| Fielding, BA | 1 |
| Collins, J | 1 |
| Hodson, L | 1 |
| Humphreys, SM | 1 |
| Frayn, KN | 1 |
| Karpe, F | 1 |
| Valizadeh, N | 1 |
| Tehrani, MR | 1 |
| Amoli, MM | 1 |
| Bandarian, F | 1 |
| Collet-Gaudillat, C | 1 |
| Billon-Bancel, A | 1 |
| Beressi, JP | 1 |
| Iwanishi, M | 1 |
| Kusakabe, T | 1 |
| Chen, W | 1 |
| Ito, J | 1 |
| Masuzaki, H | 1 |
| Hosoda, K | 1 |
| Nakao, K | 1 |
| Moreau, F | 1 |
| Boullu-Sanchis, S | 1 |
| Vigouroux, C | 1 |
| Lucescu, C | 1 |
| Lascols, O | 1 |
| Sapin, R | 1 |
| Ruimy, D | 1 |
| Guerci, B | 1 |
| Pinget, M | 1 |
| Jeandidier, N | 1 |
| Sleilati, GG | 1 |
| Leff, T | 1 |
| Bonnett, JW | 1 |
| Hegele, RA | 1 |
9 other studies available for pioglitazone and Dunnigan Syndrome
| Article | Year |
|---|---|
Clinical characteristics and efficacy of pioglitazone in a Japanese patient with familial partial lipodystrophy due to peroxisome proliferator-activated receptor γ gene mutation.
Topics: Adiponectin; Adult; Diabetes Mellitus; East Asian People; Female; Humans; Insulin Resistance; Lipody | 2023 |
A Pharmacogenetic Approach to the Treatment of Patients With
Topics: Adolescent; Adult; Amino Acid Substitution; Binding Sites; Female; Gene Expression Regulation; Genes | 2018 |
[Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia].
Topics: Caloric Restriction; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin Resistance; Lamin Type | 2015 |
Fatty acid metabolism in patients with PPARgamma mutations.
Topics: Adipose Tissue; Adult; Amino Acid Substitution; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, | 2008 |
Severe acanthosis nigricans in a 17 year-old female with partial lipodystrophic syndrome.
Topics: Acanthosis Nigricans; Adolescent; Diet Therapy; Diet, Carbohydrate-Restricted; Diet, Fat-Restricted; | 2008 |
Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report.
Topics: Adipose Tissue; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; | 2009 |
Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy.
Topics: Absorptiometry, Photon; Adiponectin; Adiposity; Blood Glucose; Body Composition; Diabetes Complicati | 2009 |
Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report.
Topics: Adipose Tissue; Adult; Body Mass Index; Body Size; Female; Humans; Hypoglycemic Agents; Lipodystroph | 2007 |
Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome.
Topics: Adult; Clofibric Acid; Female; Humans; Hypoglycemic Agents; Insulin; Lipodystrophy, Familial Partial | 2007 |